Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Phenylacetic acid derivatives as hPPAR agonists.

Santini C, Berger GD, Han W, Mosley R, MacNaul K, Berger J, Doebber T, Wu M, Moller DE, Tolman RL, Sahoo SP.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.

PMID:
12657263
2.

Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.

Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, W├Âldike HF, Fleckner J, Andersen AS, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM.

J Med Chem. 2002 Feb 14;45(4):789-804.

PMID:
11831892
3.

A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.

Dey D, Medicherla S, Neogi P, Gowri M, Cheng J, Gross C, Sharma SD, Reaven GM, Nag B.

Metabolism. 2003 Aug;52(8):1012-8.

PMID:
12898466
4.

Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.

Liu YL, Sennitt MV, Hislop DC, Crombie DL, Heyman RA, Cawthorne MA.

Int J Obes Relat Metab Disord. 2000 Aug;24(8):997-1004.

PMID:
10951538
5.

Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.

Reddy KA, Lohray BB, Bhushan V, Bajji AC, Reddy KV, Reddy PR, Krishna TH, Rao IN, Jajoo HK, Rao NV, Chakrabarti R, Dileepkumar T, Rajagopalan R.

J Med Chem. 1999 Jun 3;42(11):1927-40.

PMID:
10354401
6.

5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.

Koyama H, Boueres JK, Han W, Metzger EJ, Bergman JP, Gratale DF, Miller DJ, Tolman RL, MacNaul KL, Berger JP, Doebber TW, Leung K, Moller DE, Heck JV, Sahoo SP.

Bioorg Med Chem Lett. 2003 May 19;13(10):1801-4.

PMID:
12729668
7.

[Rosiglitazone (BRL-49653)].

Kameda N, Okuya S, Oka Y.

Nihon Rinsho. 2000 Feb;58(2):401-4. Review. Japanese.

PMID:
10707565
8.

Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives.

Madhavan GR, Chakrabarti R, Vikramadithyan RK, Mamidi RN, Balraju V, Rajesh BM, Misra P, Kumar SK, Lohray BB, Lohray VB, Rajagopalan R.

Bioorg Med Chem. 2002 Aug;10(8):2671-80.

PMID:
12057656
9.

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF.

Diabetes. 2002 Apr;51(4):1083-7.

10.

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.

Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, Chakrabarti R, Vikramadithyan RK, Misra P, Juluri S, Mamidi NV, Rajagopalan R.

J Med Chem. 2001 Aug 2;44(16):2675-8.

PMID:
11472221
12.

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW.

Diabetes. 1994 Oct;43(10):1203-10.

PMID:
7926289
13.

Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.

Reddy KA, Lohray BB, Bhushan V, Reddy AS, Rao Mamidi NV, Reddy PP, Saibaba V, Reddy NJ, Suryaprakash A, Misra P, Vikramadithyan RK, Rajagopalan R.

J Med Chem. 1999 Aug 26;42(17):3265-78.

PMID:
10464013
14.
15.

Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.

Vikramadithyan RK, Chakrabarti R, Misra P, Premkumar M, Kumar SK, Rao CS, Ghosh A, Reddy KN, Uma C, Rajagopalan R.

Metabolism. 2000 Nov;49(11):1417-23.

PMID:
11092504
16.

Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.

Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ.

Mol Pharmacol. 2001 Apr;59(4):765-73.

PMID:
11259621
17.

Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.

Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K.

Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.

PMID:
9932726
18.

Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.

Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller DE.

Endocrinology. 1998 Dec;139(12):5034-41.

PMID:
9832442
19.

[Perspective for development of insulin sensitizers].

Kadowaki T.

Nihon Rinsho. 2002 Sep;60 Suppl 9:566-72. Review. Japanese. No abstract available.

PMID:
12387052
20.

Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.

Desouza CV, Murthy SN, Diez J, Dunne B, Matta AS, Fonseca VA, McNamara DB.

J Cardiovasc Pharmacol Ther. 2003 Dec;8(4):297-305.

PMID:
14740079

Supplemental Content

Support Center